Diabetic retinopathy has long been treated as a disease of leaky, fragile blood vessels, with anti-VEGF injections as a cornerstone of care. But a growing body of research suggests the story starts earlier — in the retina's neurons and glia — well before the classic vascular signs appear. In this episode, Dr. Saikumar Gandapodi joins us to unpack what it means to view diabetic retinopathy as a neurovascular disease.

We explore the unit that links neurons, glia, and vessels, why anti-VEGF therapy is powerful yet incomplete, and where mechanisms like oxidative stress, chronic inflammation, and neurotrophin decline may fit. Dr. Gandapodi explains how the Netra Restoration Therapy framework approaches the eye as part of a whole metabolic system — always as a complement to, never a replacement for, standard ophthalmic care.

Throughout, we stay honest about the evidence: separating what's established from what's still emerging, distinguishing lab and animal work from human trials, and focusing on what patients living with diabetes can actually take away today.

Music

Welcome to the Netra Eye Institute Podcast,

where modern vision science meets the wisdom of integrative ophthalmology.

Today, we are joined by Dr. Saikumar Gandapodi,

founder and director of Netra Eye Institute,

whose work is dedicated to redefining how patients understand and approach chronic

and degenerative eye conditions. His goal is simple:

to help patients, families, and clinicians explore a more comprehensive and

integrative approach to long-term eye health.

This is the Netra Eye Institute Podcast. Let's begin.

Welcome to the show.

Today, we're looking at diabetic retinopathy through a lens that's been

gaining traction in the research world,

the idea that it's not purely a blood vessel disease, but a neurovascular one.

With me is Dr. Saikumar Gandapodi, board-certified doctor of Oriental

medicine and Ayurvedic practitioner and founder and director of the Netra Eye

Institute, a holistic eye care center.

-Dr. Gandepudi, welcome. -Thank you. Glad to be here.

This is a topic I think about a lot because it reframes when the disease

actually begins.

Let's start simple.

Most people, and honestly many patients, think of diabetic retinopathy as damaged,

leaky vessels in the back of the eye.

What's missing from that picture?

That picture is accurate, just incomplete.

The leaky vessels are real, and they matter.

But evidence suggests the retina's neurons and support cells may be in trouble

before those vessels show visible damage.

When you say neurons, the retina is nervous tissue, right? Not just plumbing.

Exactly. The retina is an outgrowth of the brain. It has photoreceptors, ganglion

cells, and glial cells like Müller cells and astrocytes.

Those cells, the neurons, and the blood vessels work together as one functional

-system. -There's a term for that system, the

neurovascular unit.

Can you explain it in plain language?

Think of it as a tightly coupled team.

The neurons signal how much energy they need, the glial cells relay that message,

and the vessels adjust blood flow to match.

When diabetes disrupts that conversation, the whole unit starts to fail together.

What's the actual evidence that neural damage comes early? How do we know it's

-not just the vessels leaking first? -Functional tests give us hints.

Studies using electroretinography and contrast or color sensitivity have found

subtle neural changes in some diabetic patients before classic retinopathy is

visible. And OCT imaging has shown thinning of the inner retinal nerve layers

early in the disease.

So the tools we already use in clinic can detect this?

Some of it, yes. OCT is routine.

But I want to be honest,

measuring inner retinal thinning and knowing exactly what to do about it early

are two different things.

The detection is ahead of the proven intervention.

Let's talk mechanisms.

If neurons are getting hurt early, what's actually driving that in a diabetic

retina?

A few processes seem to converge.

Chronic high glucose fuels oxidative stress and low-grade inflammation.

There's evidence of excitotoxicity, glutamate not being cleared properly,

which overstimulates neurons,

and mitochondrial dysfunction since the retina is one of the most energy-hungry

tissues in the body.

Glutamate clearance, that's a Müller cell job, isn't it?

It is.

Müller cells normally mop up glutamate and recycle it.

In diabetic models, that clearance appears impaired, so glutamate lingers and can

push neurons toward excitotoxic injury.

Much of that detailed work is from animal and lab studies,

so I'd frame it as strong mechanistic evidence rather than settled human proof.

You mentioned inflammation.

How does that fit with the vascular damage we see later?

Inflammation may be the bridge between the neural and vascular parts.

Cytokines like TNF alpha,

IL-one beta, and IL-six rise in the diabetic retina.

They can injure neurons and also weaken the blood retinal barrier, which sets up

the leakage we see on exams.

And where do neurotrophins come in? You've written about those.

Neurotrophins are survival signals for neurons, molecules like BDNF and NGF.

There's evidence in diabetic models that these support factors decline,

which may leave retinal neurons more vulnerable.

In humans, it's still an emerging area, more hypothesis-generating than

established therapy.

Let's be fair to conventional care.

Anti-VEGF injections have been a genuine breakthrough. Where do they fit in this

neurovascular view?

They're one of the most important advances in retina care, full stop. Anti-VEGF

drugs reduce abnormal vessel growth and leakage, and they've saved a lot of

vision, especially in diabetic macular edema and proliferative disease.

Nothing I say should be read as diminishing that.

So where's the limitation?

VEGF is one signal, mostly on the vascular side.

It's also a survival factor for neurons, which is why the story is complicated

Anti-VEGF addresses the leakage beautifully, but it doesn’t directly

target the earlier oxidative, inflammatory, and neural changes.

And it treats a later stage, not the origin.

That’s an interesting tension.

VEGF is bad in excess, but also protects neurons?

Right, and that nuance is why researchers are cautious.

It’s a reminder that these pathways aren’t simply good or bad. The clinical benefit

of anti-VEGF is clear. The neural biology just tells us there’s more happening

upstream.

So if the disease starts upstream, the obvious question is prevention.

What does the evidence actually support?

The strongest, most established levers are systemic:

glycemic control, blood pressure, and lipids.

Landmark trials in Type 1 and Type 2 diabetes showed that tighter glucose

control reduces retinopathy risk.

That’s the foundation everything else builds on.

That’s almost unglamorous advice, but it’s the highest-evidence piece.

It is,

and I never want to skip past it.

If someone optimizes their metabolic health and keeps regular dilated eye

exams, they’ve done the two most powerful things known.

Everything integrative is a complement to that, not a substitute.

Let’s get into your framework.

You founded the Netra Eye Institute and developed something called Netra

Restoration Therapy.

What is it?

Netra Restoration Therapy, or NRT, is a full-spectrum integrative approach.

Instead of aiming at a single molecule, it tries to support several biological

pathways at once: ocular blood flow, mitochondrial function,

oxidative stress balance, inflammatory balance, and neural resilience,

alongside whole-body metabolic health.

And to be clear about what it is and isn’t?

It’s an adjunct. It complements standard ophthalmic care—the exams, the injections,

the laser, the surgery. It never replaces them.

I make no cure claims and no guarantees.

The research is evolving, and I tell patients that plainly.

Why go after multiple pathways instead of one clean target?

Because a neurovascular disease is multifactorial.

Oxidative stress, inflammation, energy failure, and vascular dysfunction feed

each other.

A single-target approach can miss the web.

That’s the logic. I’d stress it’s a rationale supported by mechanism more than

by large human trials of the full program.

You come from Ayurvedic and oriental medicine traditions. How do you translate

-those ideas without overselling them? -I treat them as interpretive frameworks,

not scientific equivalents.

In Ayurveda, a diabetic state relates to disturbed metabolism affecting the tissues

and the blood,

rakta dhatu.

In Chinese medicine, there’s the concept of blood stasis and impaired circulation.

I use those as parallels to what we now describe as microvascular and metabolic

-dysfunction. -So the concept of blood stasis maps

loosely onto impaired retinal perfusion?

Loosely, yes,

and I want that word to stand.

It’s a conceptual bridge that helps me think about circulation and stagnation,

not a one-to-one biological claim.

The modern measurement is what I actually rely on.

Let’s talk herbs, because that’s where people get skeptical fast.

How do you frame herbal formulas scientifically?

Through network pharmacology.

A single botanical formula contains many phytochemicals that can touch several

pathways:

antioxidant, anti-inflammatory, and vascular. For a multifactorial disease,

that multi-target quality is interesting.

But interesting is not the same as proven.

Is there anything with real human data you’d actually point to?

There are compounds studied for diabetic retinopathy.

For example, some trials have examined a flavonoid and diosmin combination for

microvascular symptoms.

And antioxidants like lutein and zeaxanthin have retinal data in other

contexts.

For diabetic retinopathy specifically,

most of this is early or mixed,

so I present it as promising, not conclusive.

What about the gut?

There’s a lot of buzz around a gut-eye axis.

-Is that real here? -It’s a genuinely active research area.

In diabetes, the gut microbiome shifts, and that can influence systemic

inflammation and metabolic control, which in turn touch the retina.

The link is biologically plausible, and there’s growing data,

but for diabetic retinopathy, it’s still emerging. I wouldn’t tell anyone a

probiotic saves vision.

Let’s talk blood flow specifically, since it sits between the vascular and neural

worlds.

Retinal autoregulation, the ability to match blood flow to neural demand, appears

impaired early in diabetes.

Endothelial dysfunction is part of that. If neurons can’t get reliable oxygen and

fuel, that stress compounds everything else.

Supporting vascular health systemically is one place where integrative and

conventional goals overlap nicely.

For someone newly diagnosed with diabetes, worried about their eyes,

what’s the practical sequence?

First, get the metabolic fundamentals right with your physician—glucose, blood

pressure, lipids.

Second, get a dilated eye exam on the schedule your eye doctor sets, because

early disease is often silent.

Those two steps carry the most evidence.

And then where does the integrative layer come in?

Then we talk lifestyle and adjuncts. A diet rich in colorful plants, regular

movement, sleep, not smoking, and, where appropriate, targeted support discussed

openly with the whole care team.

It should be coordinated, not secret, and never a reason to skip an injection or a

laser treatment that’s indicated.

If the neurovascular model is right,

what do you hope changes in how we treat this disease in the next decade?

I’d hope we intervene earlier, at the neural and metabolic stage,

and that we develop neuroprotective strategies that sit alongside anti-VEGF

rather than replacing it. Some early-phase work on neuroprotection in diabetic

retina exists,

but we don’t yet have strong, practice-changing human trials.

That’s the frontier.

What’s the single biggest misconception you’d want to correct?

That nothing is happening until you see spots or bleeding.

The retina may be quietly stressed long before that.

It’s an argument for prevention and monitoring, not for panic.

Last question.

What should patients genuinely take away from this conversation?

Diabetic retinopathy is a whole-eye, whole-body process, not just leaky

vessels.

Control your diabetes, keep your exams, and use standard treatments when they’re

indicated.

Integrative care like NRT can be a thoughtful complement—honestly framed,

evidence-informed, and always alongside your ophthalmologist.

Dr. Gandapodi, thank you for a careful and honest conversation.

My pleasure. Thanks for having me.